Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

April 10, 2024

https://www.globenewswire.com/news-release/2024/04/10/2860669/0/en/Qualigen-Therapeutics-Novel-Direct-Pan-RAS-Inhibitors-Presented-at-American-Association-of-Cancer-Research-AACR-2024-Annual-Meeting.html

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors

CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq:QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.